Amgen will now move ahead with a phase 2 programme for AMG 133, as it tries to enter a weight-loss category that has been transformed by the approval of Novo Nordisk’s once-weekly GLP-1 agonist ...

MariTide (maridebart cafraglutide; previously AMG 133) has emerged as one of Amgen's most promising pipeline projects thanks to its potential to offer once-monthly or even less frequent dosing ...

While its adjusted earnings surged 133.3% year over year to $0.32 per share ... More news from Barchart Is Amgen Stock a Buy, Sell, or Hold as Weight-Loss Drug Trials Kick Off?

Biotech and technology weighed on the Nasdaq composite, knocking stocks sharply lower Monday afternoon, while losses in Merck and other blue chips overshadowed 3M's improved forecast among Dow Jones ...

In early February, Amgen released financial results for the 4th quarter of 2024, which I was eagerly awaiting. In addition to demonstrating efficacy in the treatment of nasal polyps in Phase 3 ...

US drug major Amgen on Monday announced the opening of its new technology and innovation site in Hyderabad. The company said it plans to invest $200 million through 2025, with additional ...

The US-based drug maker Amgen has set up a new technology and innovation centre in Hyderabad and is planning to invest $200 million through 2025, with additional sustained investments planned ove ...

Som Chattopadhyay, national executive India, Amgen, said the first 300 employees were hired within 78 days of signing the contract for the new facility and another 300 are to be onboarded soon ...

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

HYDERABAD, India (Reuters) - U.S. drugmaker Amgen will invest about $200 million this year in its new technology centre in southern India, with further investments planned, CEO Robert Bradway said ...